Patient Leaflet Updated 11-Jun-2025 | Eisai Ltd
Lenvatinib Eisai 4mg and 10mg hard capsules
Lenvatinib Eisai 4 mg hard capsules
Lenvatinib Eisai 10 mg hard capsules
1. What Lenvatinib Eisai is and what it is used for
2. What you need to know before you take Lenvatinib Eisai
3. How to take Lenvatinib Eisai
4. Possible side effects
5. How to store Lenvatinib Eisai
6. Contents of the pack and other information
Lenvatinib Eisai is a medicine that contains the active substance lenvatinib. It is used in combination with pembrolizumab as the first treatment for adults with advanced kidney cancer (advanced renal cell carcinoma). It is also used in combination with everolimus to treat adults with advanced kidney cancer where other treatments (so-called “VEGF-targeted therapy”) have not helped stop the disease.
Lenvatinib Eisai blocks the action of proteins called receptor tyrosine kinases (RTKs), which are involved in the development of new blood vessels that supply oxygen and nutrients to cells and help them to grow. These proteins can be present in high amounts in cancer cells, and by blocking their action Lenvatinib Eisai may slow the rate at which the cancer cells multiply and the tumour grows and help to cut off the blood supply that the cancer needs.
Talk to your doctor before taking Lenvatinib Eisai if you:
Before taking Lenvatinib Eisai, your doctor may carry out some blood tests, for example to check your blood pressure and your liver or kidney function and to see if you have low levels of salt and high levels of thyroid stimulating hormone in your blood. Your doctor will discuss the results of these tests with you and decide whether you can be given Lenvatinib Eisai. You may need to have additional treatment with other medicines, to take a lower dose of Lenvatinib Eisai, or to take extra care due to an increased risk of side effects.
If you are not sure talk to your doctor before taking Lenvatinib Eisai.
During treatment of your cancer, the breakdown of tumour cells may leak substances into the blood which may lead to a group of complications called tumour lysis syndrome (TLS). This may lead to changes in your kidneys and can be life-threatening. Your doctor will observe and may give you a treatment to reduce the risk. Tell your doctor immediately if you experience signs of TLS (see section 4; Possible side effects).
Lenvatinib Eisai is not currently recommended for use in children and adolescents younger than 18 years old.
Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines. This includes herbal preparations and medicines without a prescription.
If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine.
Lenvatinib Eisai may cause side effects that can affect your ability to drive or use machines. Avoid driving or using machines if you feel dizzy or tired.
Always take this medicine exactly as your doctor has told you. Check with your doctor or pharmacist if you are not sure.
You will usually carry on taking this medicine as long as you are getting benefit.
If you take more Lenvatinib Eisai than you should, talk to a doctor or pharmacist straight away. Take the medicine pack with you.
Do not take a double dose (two doses at the same time) to make up for a forgotten dose.
What to do if you forget to take your dose depends on how long it is until your next dose.
Like all medicines, this medicine can cause side effects, although not everybody gets them. The following side effects may happen with this medicine.
The following side effects may happen with this medicine when given alone:
Very common (may affect more than 1 in 10 people)
Common (may affect up to 1 in 10 people)
Uncommon (may affect up to 1 in 100 people)
Rare (may affect up to 1 in 1,000 people)
Not Known (the following side effects have been reported since the marketing of Lenvatinib Eisai but the frequency for them to occur is not known)
The following side effects may happen with this medicine when given in combination with everolimus:
Very common (may affect more than 1 in 10 people)
Common (may affect up to 1 in 10 people)
Uncommon (may affect up to 1 in 100 people)
Rare (may affect up to 1 in 1,000 people)
Not Known (the following side effects have been reported since the marketing of Lenvatinib Eisai but the frequency for them to occur is not known)
The following side effects may happen with this medicine when given in combination with pembrolizumab:
Very common (may affect more than 1 in 10 people)
Common (may affect up to 1 in 10 people)
Uncommon (may affect up to 1 in 100 people)
Rare (may affect up to 1 in 1,000 people)
Not Known (the following side effects have been reported since the marketing of Lenvatinib Eisai but the frequency for them to occur is not known)
If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the Yellow Card Scheme at: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play and Apple App store.
By reporting side effects you can help provide more information on the safety of this medicine.
Company Contact Address: For further information on your medicine contact Medical Information at Eisai Europe Limited in Hatfield. Tel: + 44 (0) 208 600 1400.
This leaflet was last revised in 04/2025.
KISP/0075/2025
EMEA Knowledge Centre, Mosquito Way, Hatfield, Hertfordshire, AL10 9SN
http://www.eisai.eu
+44(0)208 600 1400
+44 (0)208 600 1400